

HD15 for advanced stage Hodgkin's disease: Quality assurance protocol for reduction of toxicity and the prognostic relevance of fluorodeoxyglucose-positron-emission tomography (FDG-PET) in the first-line treatment of advanced stage Hodgkin's disease

Submission date 11/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/10/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 07/10/2014	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Volker Diehl

Contact details
German Hodgkin's Lymphoma Study Group,
Herderstr. 52-54
Cologne
Germany
50924
+49/221/478-3557 (-3558)
dhsg@biometrie.uni-koeln.de

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Acronym

HD15

Study objectives

Primary aim:

Reduction of toxicity, de-escalation of chemotherapy while maintaining high freedom from treatment failure (FFTF) and overall survival (OS) rates.

Secondary aims:

Assess the influence of erythropoietin on the quality of life and the effect of FDG-PET on prognosis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hodgkin's disease

Interventions

In this trial three combinations of chemotherapy are compared in a randomised, controlled trial (open-label). In addition patients in every arm are randomly assigned to receive erythropoietin or placebo (double-blind). Restaging with PET is not allocated in a randomised fashion:

Arm A:

1. 8 x erythropoietin, cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine (BEACOPP) (escalated)
2. Erythropoietin/placebo
3. 30 Gy involved field radiotherapy if partial remission after chemotherapy and PET is positive

Arm B:

1. 6 x BEACOPP (escalated)
2. Erythropoietin/placebo
3. 30 Gy involved field radiotherapy if partial remission after chemotherapy and PET is positive

Arm C:

1. 8 x BEACOPP-14
2. Erythropoietin/placebo
3. 30 Gy involved field radiotherapy if partial remission after chemotherapy and PET is positive

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Erythropoietin, cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine (BEACOPP)

Primary outcome(s)

Freedom from treatment failure (FFTF).

Key secondary outcome(s)

Impact of erythropoietin on quality of life and prognostic significance of FDG-PET.

Completion date

01/01/2008

Eligibility

Key inclusion criteria

Chemotherapy:

1. Histologically confirmed Hodgkin's disease
2. Stage IIB and massive mediastinal involvement (tumour one third or more of the maximum intrathoracic diameter) and/or extranodal involvement, stage III, and stage IV
3. No prior therapy for Hodgkin's disease
4. Age: 18 - 60 years
5. No major organ dysfunction
6. Life expectancy greater than 3 months
7. Written informed consent

PET:

1. Chemotherapy according to the HD15-protocol
2. Response to chemotherapy
3. Partial response with residual disease of at least 2.5 cm maximum diameter

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

Chemotherapy:

1. Incomplete staging
2. Major organ dysfunction:
 - 2.1. Chronic obstructive pulmonary disease (COPD) with respiratory insufficiency
 - 2.2. Symptomatic coronary heart disease (CHD)
 - 2.3. Cardiomyopathy or heart failure (ejection fraction less than 50%)
 - 2.4. Severe hypertension
 - 2.5. Non-treatable infections
 - 2.6. White blood count less than 3000/mm³ or platelets less than 100,000/mm³ if not related to bone marrow involvement
 - 2.7. Creatinine clearance less than 60 ml/min
 - 2.8. Bilirubin greater than 2 mg/dl if not related to Hodgkin's disease
 - 2.9. Glutamic oxaloacetic transaminase (GOT)/aspartate aminotransferase (AST) greater than 100 U/l if not related to Hodgkin's disease
 - 2.10. Glutamic pyruvic transaminase (GPT)/alanine aminotransferase (ALT) greater than 100 U/l if not related to Hodgkin's disease
 - 2.11. Human immunodeficiency virus (HIV)-infection
3. Composite lymphoma
4. Prior chemotherapy or radiotherapy
5. Any history of another malignancy in the last 5 years (except for cervical carcinoma in situ and fully resected melanoma TNMpT1)
6. Pregnancy or breastfeeding
7. World Health Organisation (WHO) performance status greater than 2
8. Long term use of corticosteroids (e.g. for arthritis) or antineoplastic substances (e.g. methotrexate)
9. Expected non-compliance
10. Current therapy for epilepsy
11. Intolerabilities against study drugs

PET:

1. Diabetes mellitus
2. Elevated blood glucose (greater than 130 mg/dl)
3. Massive bone involvement (endangering stability)

Date of first enrolment

01/01/2003

Date of final enrolment

01/01/2008

Locations**Countries of recruitment**

Germany

Study participating centre
German Hodgkin's Lymphoma Study Group,
Cologne
Germany
50924

Sponsor information

Organisation
German Hodgkin's Lymphoma Study Group (Germany)

Funder(s)

Funder type
Charity

Funder Name
Deutsche Krebshilfe (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/11/2008		Yes	No
Results article	results	12/05/2012		Yes	No
Results article	results	10/06/2014		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes